摘要
Abstract
Objective:To observe the therapeutic effect of oral pidotimod on peritoneal dialysis related peritonitis.Methods:One hundred and thirty peritoneal related peritonitis patients were enrolled into two groups,the therapy group and the control group,from May 2014 to May 2016.The control group was treated with cefazolin combined with ceftazidime.And the therapy group was treated with cefazolin,ceftazidime and pidotimod.The general information,effective rates of initial and two weeks treatment,number of dialysis fluid change was compared between these two groups.Micro-inflammation condition,blood lipid and Immunology after 3 months of treatment was also measured.Results:There was no significant difference between the two groups in terms ofage,sexual,the time of dialysis,primary disease,weight,MQSGA score,BUN,Scr,Ccr and distribution of pathogens.The effective rate of initial treatment was 77.7％ in the therapy group and 80.0％ in the control group,with no significantly difference (x2=0.18,P=0.66).The effective rate of 2-week treatment was 93.3％ in the therapy group,which was significantly higher than 82.2％ in the control group (x2=4.56,P=0.03).The amount of exchanges until the occurrence of clear dialysates and until the disappearance of fever in the therapy group and the control group was 4.60±1.90 vs.5.30 ±2.60 (t=1.75,P=0.08),7.00 ±3.3 vs.7.70 ±2.50 (t=1.36,P=0.17),respectively.The amount of exchanges until the disappearance of abdominal pain was 7.75 ±2.50 in the therapy group,which was significantly lower than 11.38 ±2.70 in the control group (t=7.95,P＜0.001).The amount of exchanges until the leucocyte counts ＜50/μtL was 8.60 ±3.60 in the therapy group,which was significantly lower than 13.75 ±4.7 in the control group (t=7.10,P＜0.001).The level of hs-CRP,HMGB-1 in the therapy group was significantly lower than that in the control group after 3 months treatment.There was no significant difference between the two groups before and after treatment for 2 weeks,in the immunological index,IgG and IgA increased significantly in the treatment group after the treatment.Conclusion:Pidotimod can modify the positive rate of antibiotic treatment in peritoneal dialysis related peritonitis,and reduce the disappearance time of patients' clinical symptoms,also it can modify the micro-inflammation condition of patients.关键词
腹膜透析相关性腹膜炎/匹多莫德/免疫辅助治疗/微炎症状态Key words
peritoneal dialysis related peritonitis/pidotimod/immune adjuvant therapy/micro-inflammation
